BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19739275)

  • 1. [Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].
    Tanyi J; Rigó J
    Orv Hetil; 2009 Jun; 150(24):1109-18. PubMed ID: 19739275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.
    Mills GB; Eder A; Fang X; Hasegawa Y; Mao M; Lu Y; Tanyi J; Tabassam FH; Wiener J; Lapushin R; Yu S; Parrott JA; Compton T; Tribley W; Fishman D; Stack MS; Gaudette D; Jaffe R; Furui T; Aoki J; Erickson JR
    Cancer Treat Res; 2002; 107():259-83. PubMed ID: 11775454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer.
    Zhao P; Yun Q; Li A; Li R; Yan Y; Wang Y; Sun H; Damirin A
    Med Oncol; 2022 Jan; 39(2):17. PubMed ID: 34982278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
    Tanyi JL; Hasegawa Y; Lapushin R; Morris AJ; Wolf JK; Berchuck A; Lu K; Smith DI; Kalli K; Hartmann LC; McCune K; Fishman D; Broaddus R; Cheng KW; Atkinson EN; Yamal JM; Bast RC; Felix EA; Newman RA; Mills GB
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3534-45. PubMed ID: 14506139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
    Yu X; Zhang Y; Chen H
    BMC Cancer; 2016 Nov; 16(1):846. PubMed ID: 27809800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer.
    Fujita T; Miyamoto S; Onoyama I; Sonoda K; Mekada E; Nakano H
    Cancer Lett; 2003 Mar; 192(2):161-9. PubMed ID: 12668280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of lysophosphatidic acid receptor in human ovarian cancer cell lines 3AO, SKOV3, OVCAR3 and its significance].
    Wang P; Wu XH; Chen WX; Shan BE; Guo Q
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Nov; 25(11):1422-4, 1431. PubMed ID: 16305971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA
    Park J; Jang JH; Oh S; Kim M; Shin C; Jeong M; Heo K; Park JB; Kim SR; Oh YS
    Cell Signal; 2018 Apr; 44():138-147. PubMed ID: 29329782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells.
    Hu YL; Albanese C; Pestell RG; Jaffe RB
    J Natl Cancer Inst; 2003 May; 95(10):733-40. PubMed ID: 12759391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor.
    Chou CH; Wei LH; Kuo ML; Huang YJ; Lai KP; Chen CA; Hsieh CY
    Carcinogenesis; 2005 Jan; 26(1):45-52. PubMed ID: 15471896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.
    Mukherjee A; Wu J; Barbour S; Fang X
    J Biol Chem; 2012 Jul; 287(30):24990-5000. PubMed ID: 22665482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
    Tanyi JL; Morris AJ; Wolf JK; Fang X; Hasegawa Y; Lapushin R; Auersperg N; Sigal YJ; Newman RA; Felix EA; Atkinson EN; Mills GB
    Cancer Res; 2003 Mar; 63(5):1073-82. PubMed ID: 12615725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment.
    Reinartz S; Lieber S; Pesek J; Brandt DT; Asafova A; Finkernagel F; Watzer B; Nockher WA; Nist A; Stiewe T; Jansen JM; Wagner U; Konzer A; Graumann J; Grosse R; Worzfeld T; Müller-Brüsselbach S; Müller R
    Mol Oncol; 2019 Feb; 13(2):185-201. PubMed ID: 30353652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulator of G-protein signalling expression and function in ovarian cancer cell lines.
    Hurst JH; Mendpara N; Hooks SB
    Cell Mol Biol Lett; 2009; 14(1):153-74. PubMed ID: 18979070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
    Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
    Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells.
    Kim EK; Park JM; Lim S; Choi JW; Kim HS; Seok H; Seo JK; Oh K; Lee DS; Kim KT; Ryu SH; Suh PG
    J Biol Chem; 2011 Jul; 286(27):24036-45. PubMed ID: 21602274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.
    Hu YL; Tee MK; Goetzl EJ; Auersperg N; Mills GB; Ferrara N; Jaffe RB
    J Natl Cancer Inst; 2001 May; 93(10):762-8. PubMed ID: 11353786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts.
    Radhakrishnan R; Ha JH; Jayaraman M; Liu J; Moxley KM; Isidoro C; Sood AK; Song YS; Dhanasekaran DN
    Cancer Lett; 2019 Feb; 442():464-474. PubMed ID: 30503552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering a GPCR-lncrna-miRNA nexus: Identification of an aberrant therapeutic target in ovarian cancer.
    Ha JH; Radhakrishnan R; Nadhan R; Gomathinayagam R; Jayaraman M; Yan M; Kashyap S; Fung KM; Xu C; Bhattacharya R; Mukherjee P; Isidoro C; Song YS; Dhanasekaran DN
    Cancer Lett; 2024 Jun; 591():216891. PubMed ID: 38642607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells.
    Oyesanya RA; Lee ZP; Wu J; Chen J; Song Y; Mukherjee A; Dent P; Kordula T; Zhou H; Fang X
    FASEB J; 2008 Aug; 22(8):2639-51. PubMed ID: 18362203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.